Deep Biotech companies using engineering biology for good: Moa Technology case study

MOA-logo.png

A spin-out from Oxford University, Moa Technology is developing next-generation herbicides to tackle a growing crisis in agriculture. Read more in BIA's Deep Biotech report on disruptive innovation for global sustainability.


What does the company do? 

Moa Technology is developing next-generation herbicides to tackle a growing crisis in agriculture: herbicide-resistant weeds. The company was spun out of the University of Oxford in 2017 and uses the same kind of advanced approaches employed in health and medicine-focused biotech to identify, understand and develop new herbicides, with game-changing speed and accuracy. Specifically, it is developing herbicides with novel modes of action (MOAs).

Moa-900px.png

What is the impact?

Without effective herbicides, farmers can lose up to 40% of their crop yield as a result of weed growth. This means that herbicide-resistant weeds are a major threat to global agriculture and food security.

The issue is particularly pressing because of climate change and population growth. If weeds are allowed to reduce agricultural productivity, farmers will need to use more land, fertiliser, diesel, water and other inputs to produce the same amount of food, substantially increasing carbon emissions. Increased land use for farming would also reduce natural carbon sequestration, as well as impacting biodiversity and general resilience. Furthermore, farmers will need effective herbicides to grow new crops and contend with new weed mixes as crop growing areas shift as a result of climate change.

Why is biotechnology/engineering biology the solution?

Herbicide resistance is a particularly urgent international problem given a 35-year innovation drought in the established herbicide industry, which has not delivered effective new products that can counter the problem.

Working with both synthetic molecules and natural products found in organisms and ecosystems around the world, and using a discovery engine similar to those used in drug discovery, Moa’s interdisciplinary team of scientists carry out plant-led high-throughput screening to identify new modes of action. This allows them to find whole new families of herbicides that are safer and better for the environment, and more effectively choose the best candidates for investment and development into products for farmers’ fields.

How do we drive forward the biorevolution in the UK?

The UK should make the most of its remarkable expertise in biotechnology, and in science and technology more broadly. This is in the national economic interest, and vital given international challenges and the need for innovation to address them.

Among other key priorities, the Government and other stakeholders must support and encourage the incredible talent pools in the UK, and the ecosystems around its universities. Moa illustrates these points well. Its technology was developed within the University of Oxford’s Department of Plant Sciences by a professor and his French PhD student, and today it employs an international team of more than 60 drawn from disciplines including chemistry, biotechnology, agriculture and artificial intelligence/machine learning.

What are the opportunities and challenges?

The potential for next-generation herbicides is huge, both in overcoming the immediate challenge of herbicide resistant weeds, and in providing superior performance across a range of other criteria. Moa has a prolific pipeline of both traditional and bioherbicide leads that work in new ways. Additional industry partnerships, robust yet responsive regulation, and international collaboration between governments and regulators all have a vital role to play, too.

Although Moa has strong financial backing, the challenge for governments and other stakeholders is to ensure more broadly that the UK’s cutting-edge biotechnology and research continues to be developed to support scale-up businesses that address key challenges facing the world.


 

More news and updates 

CEO Update - 20 May 2024

The UK continues to lead the global discussion on tackling the antibiotic emergency. Last week saw leading global figures convene at the Royal Society to pledge money and agree actions on the AMR agenda.

Spotlight on hearing therapeutics landscape: a clinical perspective

Professor Gerard O’Donoghue shares his perspective as Consultant Neurotologist at Nottingham University Hospitals NHS Trust on why he believes that the development of new treatments and their subsequent clinical adoption are vital for people living with hearing loss.

Deep Biotech companies using engineering biology for good: Epoch Biodesign case study

Featured in BIA's Deep Biotech report, Epoch Biodesign aims to revolutionize plastic waste management by creating tailor-made enzymes that efficiently depolymerize a wide range of plastics into recyclable materials, offering a circular solution to tackle plastic pollution and promote sustainability.

Women in Biotech Mentoring Programme: Helen and Kathryn's experience

In this interview, consultant and best-selling author Kathryn Simpson, together with patent attorney Helen Bartlett, dive into their reasons for joining the BIA's Women in Biotech mentoring programme, and how this experience has impacted their professional and personal lives.

Deep Biotech companies using engineering biology for good: Solena Materials case study

Solena Materials is a pioneering biotech company spun out from Imperial College London, specialising in the development of computationally designed synthetic protein materials, originally featured in BIA's Deep Biotech report on disruptive innovation for global sustainability.

CEO Update - 13 May 2024

It was wonderful to celebrate with RNID, our charity partner of the year, the news that pioneering gene therapy has restored a UK girl's hearing. Read on for updates on MHRA AI-Airlock, AMR action plan and more...

Accelerating biotech innovations and predicting genetic codes: Spotlight on Ingenza

Meet Ian Fotheringham, the Managing Director of Ingenza, a global CRDMO that aims to accelerate clients' journeys from discovery to clinical trials while minimising costs and risks. Their innovative codABLE® algorithm brings predictability to DNA sequence configuration, revolutionizing recombinant production of pharmaceutical and industrial molecules. Join us as we explore Ian's insights and Ingenza's ambitious goals for the future.

Deep Biotech companies using engineering biology for good: Moa Technology case study

A spin-out from Oxford University, Moa Technology is developing next-generation herbicides to tackle a growing crisis in agriculture. Read more in BIA's Deep Biotech report on disruptive innovation for global sustainability.

A critical time for AI, dementia and better brain health

Ahead of BioBeat24, Iraida Soria-Espinosa, Senior Innovation & Business Manager at UK DRI, and Miranda Weston-Smith, Founder of BioBeat, caught up with keynote speaker Zoe Kourtzi, Professor of Computational Cognitive Neuroscience at the University of Cambridge.

CEO Update - 7 May 2024

It’s SynBioBeta week and the UK engineering biology community is out in force in San Jose, California. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's companies. Read on for updates on local election results, Innovation Map and Deaf Awareness Week...

More within